Antoine Hollebecque

26.4k total citations · 8 hit papers
315 papers, 11.2k citations indexed

About

Antoine Hollebecque is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Antoine Hollebecque has authored 315 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 203 papers in Oncology, 101 papers in Molecular Biology and 99 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Antoine Hollebecque's work include Cancer Immunotherapy and Biomarkers (59 papers), Pancreatic and Hepatic Oncology Research (52 papers) and Cancer Genomics and Diagnostics (49 papers). Antoine Hollebecque is often cited by papers focused on Cancer Immunotherapy and Biomarkers (59 papers), Pancreatic and Hepatic Oncology Research (52 papers) and Cancer Genomics and Diagnostics (49 papers). Antoine Hollebecque collaborates with scholars based in France, United States and United Kingdom. Antoine Hollebecque's co-authors include Jean‐Charles Soria, Christophe Massard, Aurélien Marabelle, Stéphane Champiat, Charles Ferté, Samy Ammari, Michel Ducreux, Sébastien Dharancy, Philippe Mathurin and Laurent Dercle and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Antoine Hollebecque

293 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

2020 975 citations Antoine Hollebecque, Do‐Youn Oh et al. profile →
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015 941 citations Michel Ducreux, Caroline Caramella et al. Annals of Oncology profile →
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

2016 867 citations Stéphane Champiat, Laurent Dercle et al. Clinical Cancer Research profile →
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

2018 825 citations Roger Sun, Laurent Dercle et al. profile →
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

2018 362 citations Antoine Hollebecque et al. profile →
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

2019 299 citations Antoine Hollebecque, Emiliano Calvo et al. Journal of Clinical Oncology profile →
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

2019 272 citations Jean‐Marie Michot, Andréa Varga et al. profile →
Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

2020 191 citations Antoine Hollebecque, Luc Friboulet et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antoine Hollebecque France	45	6.4k	3.1k	3.1k	2.2k	2.1k	315	11.2k
Jean‐Luc Van Laethem Belgium	44	7.9k 1.2×	3.4k 1.1×	3.2k 1.0×	1.4k 0.6×	1.6k 0.8×	275	10.4k
Eric Assénat France	38	7.2k 1.1×	2.1k 0.7×	2.5k 0.8×	1.9k 0.9×	2.0k 0.9×	176	10.2k
Jean‐Baptiste Bachet France	39	11.4k 1.8×	2.7k 0.9×	4.2k 1.4×	2.5k 1.2×	2.0k 0.9×	213	13.5k
Ari David Baron United States	25	7.6k 1.2×	2.3k 0.7×	3.4k 1.1×	3.5k 1.6×	852 0.4×	71	12.9k
George Fountzilas Greece	54	7.7k 1.2×	2.3k 0.7×	3.7k 1.2×	3.1k 1.4×	955 0.5×	576	12.8k
Baek‐Yeol Ryoo South Korea	50	4.8k 0.7×	2.1k 0.7×	3.3k 1.1×	1.4k 0.7×	1.8k 0.9×	349	10.1k
Robert R. McWilliams United States	46	5.9k 0.9×	1.9k 0.6×	1.9k 0.6×	2.4k 1.1×	1.1k 0.5×	206	8.4k
Junji Furuse Japan	54	6.6k 1.0×	4.7k 1.5×	3.7k 1.2×	2.2k 1.0×	2.9k 1.4×	421	12.7k
Antoine Adenis France	40	10.4k 1.6×	4.0k 1.3×	5.4k 1.8×	2.2k 1.0×	1.7k 0.8×	213	14.2k
Inne H.M. Borel Rinkes Netherlands	52	3.1k 0.5×	3.6k 1.2×	2.2k 0.7×	1.7k 0.8×	1.2k 0.6×	277	9.4k

Countries citing papers authored by Antoine Hollebecque

Since Specialization

Citations

This map shows the geographic impact of Antoine Hollebecque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoine Hollebecque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoine Hollebecque more than expected).

Fields of papers citing papers by Antoine Hollebecque

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antoine Hollebecque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoine Hollebecque. The network helps show where Antoine Hollebecque may publish in the future.

Co-authorship network of co-authors of Antoine Hollebecque

This figure shows the co-authorship network connecting the top 25 collaborators of Antoine Hollebecque. A scholar is included among the top collaborators of Antoine Hollebecque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoine Hollebecque. Antoine Hollebecque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eid, Roland, Pierre Decazes, C. David, et al.. (2025). Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. Future Oncology. 21(6). 691–697.

Segal, Neil H., Jeanne Tie, Scott Kopetz, et al.. (2024). COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. British Journal of Cancer. 131(6). 1005–1013. 3 indexed citations

Peters, Solange, Antoine Hollebecque, Kartik Sehgal, et al.. (2024). Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).. Journal of Clinical Oncology. 42(16_suppl). 8521–8521. 3 indexed citations

Perets, Ruth, Manish Sharma, John H. Strickler, et al.. (2024). Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications.. Journal of Clinical Oncology. 42(16_suppl). TPS3162–TPS3162.

Burns, Timothy F., Konstantin H. Dragnev, Yutaka Fujiwara, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(16_suppl). 8510–8510. 22 indexed citations

Meric‐Bernstam, Funda, Antoine Hollebecque, Junji Furuse, et al.. (2024). Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical Cancer Research. 30(8). 1466–1477. 8 indexed citations

Fujiwara, Yutaka, Timothy F. Burns, Konstantin H. Dragnev, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(23_suppl). 195–195. 2 indexed citations

Leroy, Karen, Clarisse Audigier-Valette, Jérôme Alexandre, et al.. (2023). Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study). PLoS ONE. 18(9). e0291495–e0291495. 3 indexed citations

Nicolle, Rémy, Valérie Boige, T. Pudlarz, et al.. (2023). Precision medicine for KRAS wild-type pancreatic adenocarcinomas. European Journal of Cancer. 197. 113497–113497. 16 indexed citations

10.

Gazzah, Anas, Ratislav Bahleda, Antoine Hollebecque, et al.. (2023). Profile and outcome of cancer patients enrolled in contemporary phase I trials. European Journal of Cancer. 188. 1–7. 2 indexed citations

11.

Michel, Loren S., Antonio Jimeno, Ammar Sukari, et al.. (2023). 859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial. Annals of Oncology. 34. S558–S558. 8 indexed citations

12.

Baldini, Capucine, P. Martin Romano, Anne-Laure Voisin, et al.. (2020). Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies. European Journal of Cancer. 129. 71–79. 63 indexed citations

13.

Varga, Andréa, Jean‐Charles Soria, Antoine Hollebecque, et al.. (2019). A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(6). 1229–1236. 64 indexed citations

14.

Facchinetti, Francesco, Antoine Hollebecque, Rastislav Bahleda, et al.. (2019). Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. Clinical Cancer Research. 26(4). 764–774. 88 indexed citations

15.

Tsélikas, Lambros, Roger Sun, Samy Ammari, et al.. (2019). Role of image-guided biopsy and radiomics in the age of precision medicine. Chinese Clinical Oncology. 8(6). 57–57. 18 indexed citations

16.

Gauci, Marie-Léa, Émilie Lanoy, Stéphane Champiat, et al.. (2018). Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research. 25(3). 946–956. 106 indexed citations

17.

Champiat, Stéphane, Laurent Dercle, Samy Ammari, et al.. (2016). Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clinical Cancer Research. 23(8). 1920–1928. 867 indexed citations breakdown →

18.

Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2016). Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research. 23(10). 2423–2432. 59 indexed citations

19.

Gupta, Shilpa, Guillem Argilés, Pamela N. Münster, et al.. (2015). A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clinical Cancer Research. 21(23). 5235–5244. 27 indexed citations

20.

Ferté, Charles, Antoine Hollebecque, Serge Koscielny, et al.. (2013). Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. Clinical Cancer Research. 20(1). 246–252. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact